Zai Lab Limited (ZLAB) 10-Q2022 Q2 Quarterly report

Filed: 9 Aug 22, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: abusing, advantage, advisory, affiliated, aged, alfa, amenable, AML, ASCO, award, bad, broadly, BTD, Chair, Chairperson, CIIO, CNS, codify, Cohen, concurrently, CR, CSL, cutoff, DAL, DCR, deprioritize, developmental, Diekman, difficulty, dominance, driven, dual, efficiency, England, facilitate, fairly, fewer, FIGHT, gMG, greatest, ground, guided, Hainan, IC, immunotherapy, Incyte, interval, intracranial, John, joined, Josh, Journal, Lecheng, liaison, licensor, Marder, mDOR, member, mg, modest, monopolistic, monopoly, Morrison, mOS, neurological, omitted, organize, ORR, outlining, oversee, PI, PIPC, PR, preceding, preference, prespecified, prioritization, prioritizing, prove, provincial, qualified, recommended, rectify, Regeneron, remedial, resale, residual, resume, retifanlimab, revealed, SC, schizophrenia, Scott, shift, side, simurosertib, Speaker, spread, strategic, subgroup, subset, suited, SYMPHONY, Syndrome, thereunder, Tourism, trastuzumab, untreated, vertical, visit, vote, voting, Week, withheld, women, Zone

Removed: addressed, administered, AHFCA, Article, attract, attribution, began, Chairwoman, civil, classification, closely, collection, compensate, consent, court, criteria, debt, deemed, deprived, discovery, disposal, disruption, Du, enforce, exercising, exist, export, fee, gain, hereinafter, improve, invested, jointly, judicial, locally, manner, opinion, pivotal, Pool, practical, preclinical, President, prevention, protected, publicly, registration, regular, regulated, render, respond, Samantha, single, steadily, suffer, sufficiently, summary, supervision, Treating, tumor, unknown, unresectable, yearly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ZLAB transcripts

ZLAB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification by the Principal Executive Officer

Pursuant to 18 U.S.C. Section 1350,

As Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 of Zai Lab Limited (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Samantha (Ying) Du, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 9, 2022			/s/ Samantha (Ying) Du
			Samantha (Ying) Du
			Chief Executive Officer
			(Principal Executive Officer)